The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
Open accessAbstract
Belumosudil, an investigational oral selective inhibitor of Rho-associated coiled-coil–containing protein kinase 2 (ROCK2), reduces type 17 and follicular T helper cells via downregulation of STAT3 and enhances regulatory T cells via upregulation of STAT5. Belumosudil may effectively treat patients with chronic graft-versus-host disease (cGVHD), a major cause of morbidity and late nonrelapse mortality after an allogeneic hematopoietic cell transplant. This phase 2 randomized multicenter registration study evaluated belumosudil 200 mg daily (n = 66) and 200 mg twice daily (n = 66) in subjects with cGVHD who had received 2 to 5 prior lines of therapy. The primary end point was best overall response rate (ORR). Duration of response (DOR), changes in Lee Symptom Scale score, failure-free survival, corticosteroid dose reductions, and overall survival were also evaluated. Overall median follow-up was 14 months. The best ORR for belumosudil 200 mg daily and 200 mg twice daily was 74% (95% confidence interval [CI], 62-84) and 77% (95% CI, 65-87), respectively, with high response rates observed in all subgroups. All affected organs demonstrated complete responses. The median DOR was 54 weeks; 44% of subjects have remained on therapy for ≥1 year. Symptom reduction with belumosudil 200 mg daily and 200 mg twice daily was reported in 59% and 62% of subjects, respectively. Adverse events (AEs) were consistent with those expected in patients with cGVHD receiving corticosteroids and other immunosuppressants. Sixteen subjects (12%) discontinued belumosudil because of possible drug-related AEs. Belumosudil, a promising therapy for cGVHD, was well tolerated with clinically meaningful responses. This trial was registered at www.clinicaltrials.gov as #NCT03640481.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1703472 · Cited by 748
Self-citationLong-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation
Wingard, J. R., Majhail, N. S., Brazauskas, R., Wang, Z., Sobocinski, K. A., Jacobsohn, D., Sorror, M. L., Horowitz, M. M., Bolwell, B., Rizzo, J. D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7212 · Cited by 632
Pavletic, S. Z., Martin, P., Lee, S. J., Mitchell, S., Jacobsohn, D., Cowen, E. W., Turner, M. L., Akpek, G., Gilman, A., McDonald, G., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.01.008 · Cited by 563
Self-citationLee, S. J., Wolff, D., Kitko, C., Koreth, J., Inamoto, Y., Jagasia, M., Pidala, J., Olivieri, A., Martin, P. J., Przepiorka, D., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.02.025 · Cited by 431
Self-citationHow we treat chronic graft-versus-host disease
Flowers, M. E. D., & Martin, P. J. (2015) · Blood · doi:10.1182/blood-2014-08-551994 · Cited by 371
Wolff, D., Schleuning, M., von Harsdorf, S., Bacher, U., Gerbitz, A., Stadler, M., Ayuk, F., Kiani, A., Schwerdtfeger, R., Vogelsang, G. B., et al. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.05.011 · Cited by 327
Self-citationChronic graft-versus-host disease: biological insights from preclinical and clinical studies
MacDonald, K. P. A., Hill, G. R., & Blazar, B. R. (2017) · Blood · doi:10.1182/blood-2016-06-686618 · Cited by 300
Self-citationKoc, S., Leisenring, W., Flowers, M. E. D., Anasetti, C., Deeg, H. J., Nash, R. A., Sanders, J. E., Witherspoon, R. P., Storb, R., Appelbaum, F. R., et al. (2002) · Blood · doi:10.1182/blood.v100.1.48 · Cited by 283
Zanin-Zhorov, A., Weiss, J. M., Nyuydzefe, M. S., Chen, W., Scher, J. U., Mo, R., Depoil, D., Rao, N., Liu, B., Wei, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414189111 · Cited by 262
Self-citationDevelopment and validation of a scale to measure symptoms of chronic graft-versus-host disease
Lee, S. J., Cook, E. F., Soiffer, R., & Antin, J. H. (2002) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2002.v8.pm12234170 · Cited by 246
Self-citation
Cited by
Penack, O., Marchetti, M., Aljurf, M., Arat, M., Bonifazi, F., Duarte, R. F., Giebel, S., Greinix, H., Hazenberg, M. D., Kröger, N., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00342-3 · Cited by 262
Zanin-Zhorov, A., & Blazar, B. R. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108823 · Cited by 74
Self-citation
Metadata
- Authors
- Cutler, C., Lee, S. J., Arai, S., Rotta, M., Zoghi, B., Lazaryan, A., Ramakrishnan, A., DeFilipp, Z., Salhotra, A., Chai-Ho, W., Mehta, R., Wang, T., Arora, M., Pusic, I., Saad, A., Shah, N. N., Abhyankar, S., Bachier, C., Galvin, J., Im, A., Langston, A., Liesveld, J., Juckett, M., Logan, A., Schachter, L., Alavi, A., Howard, D., Waksal, H. W., Ryan, J., Eiznhamer, D., Aggarwal, S. K., Ieyoub, J., Schueller, O., Green, L., Yang, Z., Krenz, H., Jagasia, M., Blazar, B. R., & Pavletic, S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-12-02
- Volume
- 138
- Issue
- 22
- Pages
- 2278-2289
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3095621154
- Cited by
- 354
- References
- 32
- FWCI
- 25.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. https://app.cochat.ai/papers/10.1182/blood.2021012021
- The paper
- Cutler, C., Lee, S. J., Arai, S., Rotta, M., Zoghi, B., Lazaryan, A., Ramakrishnan, A., DeFilipp, Z., Salhotra, A., Chai-Ho, W., Mehta, R., Wang, T., Arora, M., Pusic, I., Saad, A., Shah, N. N., Abhyankar, S., Bachier, C., Galvin, J., . . . Pavletic, S. (2021). Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. https://doi.org/10.1182/blood.2021012021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.